#Sweden #Stockholm #Eisai #Leqembi #BioArctic

Leqembi® Reports Impressive Sales in Q4 2025

In a remarkable achievement, Leqembi®, developed by BioArctic AB's partner Eisai, recorded global sales of 20.7 billion yen for the fourth quarter of 2025. This notable performance is part of the preliminary global revenue reported in connection with Biogen's quarterly earnings report, showcasing the drug's growing acceptance in the market.

Results Overview

The sales figure translates into a royalty payment of approximately SEK 127 million to BioArctic, reflecting a substantial increase of around 31% compared to the royalties from the fourth quarter of 2024. Such growth highlights the positive trajectory of Leqembi® amid an evolving industry landscape.

Importantly, the strong appreciation of the Swedish krona throughout 2025 significantly impacted the increase in royalties. Keeping exchange rates constant, the actual growth rate in recorded royalties in SEK would have reached nearly 50%. This highlights the influence of external economic factors on BioArctic's revenue stream from Leqembi®.

Eisai is set to publish their third-quarter financial results for FY2025 on February 9, 2026, which will offer further insights into the product's performance. Following that, BioArctic’s full-year report for 2025 is scheduled to be released on February 18, 2026, at 08:00 CET, likely stirring additional interest from both investors and industry analysts.

About Leqembi® (lecanemab)

Leqembi®, a humanized igG1 monoclonal antibody, targets aggregated forms of amyloid-beta, which are critical in the pathology of Alzheimer’s disease. Approved in 53 countries, Leqembi® is positioned as a crucial treatment option, with ongoing regulatory reviews in six additional markets. Following its initial treatment phase involving bi-weekly doses, it has received approval for maintenance dosing every four weeks in various countries including the UK, China, the US, and Japan. This adaptability in delivery methods, including subcutaneous administration via a device in the US, underscores Eisai's commitment to making Leqembi® accessible for early Alzheimer’s patients.

The drug has made significant advancements in clinical research, backed by ongoing Phase 3 studies targeting preclinical Alzheimer’s patients. The AHEAD 3-45 study, which has received strong support through public-private partnerships, is set to continue shaping the landscape of Alzheimer’s research and therapy.

Collaboration and Ongoing Efforts

The partnership between BioArctic and Eisai, which began in 2005, has fostered a nurturing environment for innovative treatments targeting Alzheimer’s disease. The long-standing collaboration includes various agreements for the development and commercialization of Leqembi® and its backup treatments. Notably, BioArctic has no direct development costs for Leqembi® and stands to gain from sales milestones and ongoing royalties. This ensures a robust financial model as they prepare for further market exploits, especially in the Nordic region where BioArctic holds exclusive commercialization rights.

In conclusion, Leqembi®’s impressive sales figures not only demonstrate its market acceptance but also highlight the effective collaboration between BioArctic and Eisai in combating Alzheimer’s disease. As both companies gear up for further developments and expansions, the coming months are anticipated to be pivotal for the future trajectory of both the drug and the companies involved. The ongoing commitment to research and development promises to yield new insights and treatment options for Alzheimer's, as they continue to focus on the health and well-being of patients globally.